Wicked Good Cardiometabolic Chat: The Treatment and Future Pipeline for Obesity Pharmacotherapy

In episode 9 of Wicked Good Cardiometabolic Chat, Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, professor of pharmacy practice at the Massachusetts College of Pharmacy and Health Sciences (MCPHS), and Hailey Choi, PharmD, BCACP, CDCES, associate professor of pharmacy practice at MCPHS, explore how new and emerging therapies are fundamentally changing clinical expectations and patient outcomes in the obesity management space.

The discussion centers on the diversification of delivery methods and the arrival of next-generation molecules. While established players like injectable semaglutide and tirzepatide remain efficacy benchmarks—often achieving weight loss between 15% and 21%—the hosts highlight the critical role of patient preference and adherence.

They break down the nuances of the newly approved oral semaglutide (Wegovy), noting its specific fasting requirements, and contrast it with orforglipron—a new, non-peptide oral glucagon-like peptide-1 (GLP-1) receptor agonist that offers greater flexibility by eliminating food restrictions.

Beyond current options, this episode also dives into the clinical excitement surrounding retatrutide. As a triple agonist targeting GLP-1, GIP, and glucagon receptors, this drug has demonstrated mean weight reductions of up to 24.2% in phase 2 trials. However, Goldman and Choi emphasize that the most sophisticated question in modern practice isn't just about the highest percentage of weight loss; it’s about tolerability, titration strategies to mitigate GI side effects, and how these therapies address comorbidities like sleep apnea, liver disease, and heart failure.

This episode serves as an essential guide for pharmacists now navigating the increasingly complex gradient of obesity care.

For more on GLP-1 medications and counseling patients on these expanding prescription regimens, check out this previous episode of Wicked Good Cardiometabolic Chat: Practical Counseling Tips for GLP-1, Dual Agonist Therapies.

In Wicked Good Cardiometabolic Chat, a podcast offering from Drug Topics, Goldman and Choi aim to empower pharmacists with evidence-based insights into various cardiometabolic topics. All new episodes of Wicked Good Cardiometabolic Chat will be available in a video format via DrugTopics.com. Check out our most recent episode: The Clinical Essentials of Finerenone.

Pharmacy practice is always changing. Stay ahead of the curve: Sign up for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.